Amyloid positron emission tomography candidates may focus more on benefits than risks of results disclosure
Abstract Introduction Given mounting calls to disclose biomarker test results to research participants, we explored factors underlying decisions by patients with mild cognitive impairment to receive amyloid imaging results. Methods Prospective, qualitative interviews were conducted with 59 participa...
Main Authors: | Jennifer H. Lingler, J. Scott Roberts, Hyejin Kim, Jonna L. Morris, Lu Hu, Meghan Mattos, Eric McDade, Oscar L. Lopez |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-01-01
|
Series: | Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring |
Subjects: | |
Online Access: | https://doi.org/10.1016/j.dadm.2018.05.003 |
Similar Items
-
Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review
by: Arno de Wilde, et al.
Published: (2018-07-01) -
FDG-PET hypermetabolism is associated with higher tau-PET in mild cognitive impairment at low amyloid-PET levels
by: Anna Rubinski, et al.
Published: (2020-10-01) -
Cross‐sectional and longitudinal atrophy is preferentially associated with tau rather than amyloid β positron emission tomography pathology
by: Brian A. Gordon, et al.
Published: (2018-01-01) -
Beta Amyloid Deposition Is Not Associated With Cognitive Impairment in Parkinson's Disease
by: Tracy R. Melzer, et al.
Published: (2019-04-01) -
Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition
by: Shannon L. Risacher, et al.
Published: (2019-12-01)